ERBB2 and breast carcinoma: A large, North American cohort (n = 46,265) that was evaluated by Murphy et al. of young women under the age of 40 with breast cancer diagnosed between 2010 and 2015 reported rates of HER2+ disease of 26.0% and triple-negative disease of 21.2% [18].